jain.com

Quarterly revenue $582.3M, up 454% YoY

Company: Nebius

Subject kind
guidance
Statement date
2026-08-13
Promised amount
582300000.0 USD
Current status
verified

The claim, verbatim

Nebius reported quarterly revenue of $582.3 million, up 454% year over year, and EPS of ($0.12) versus consensus ($0.67).

Source (primary)

Nebius Group (NASDAQ:NBIS) Stock Jumps 4.5% - Should You Buy? - MarketBeat (-, news_article)
View cached copy (2026-10-03)Live source ↗

Quote: “The firm had revenue of $582.30 million for the quarter, compared to analysts' expectations of $567.91 million.”

How we checked this

Checked on November 6, 2026. The cited source supports every part of this claim.

The MarketBeat article states that Nebius had quarterly revenue of $582.30 million, up 454% from the same quarter last year. It also reports EPS of ($0.12) against a consensus estimate of ($0.67).

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://www.marketbeat.com/instant-alerts/price-nebius-group-nasdaq-nbis-stock-jumps-45-should-you-buy-2026-10-02/) in full (20,238 characters, retrieved October 3, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Nebius Group (NASDAQ:NBIS) Stock Jumps 4.5% - Should You Buy? - MarketBeat

Quote: “The firm had revenue of $582.30 million for the quarter, compared to analysts' expectations of $567.91 million.”

View cached copy (2026-10-03)Live source ↗

confirms Nebius Group (NASDAQ:NBIS) Stock Falls 8.3% After Insider Selling - MarketBeat

Quote: “The firm had revenue of $582.30 million during the quarter, compared to analyst estimates of $567.91 million.”

View cached copy (2026-11-05)Live source ↗

Record of changes

October 3, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
November 5, 2026 — verified
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.